Asthma Respiratory Asthma
Conditions
Interventions
The I-MUR intervention covers patients’ demographics, their regular medications including those used for asthma, patients’ attitudes towards their medications and adherence to treatments, pharmaceutic
Sponsors
FOFI (Italian Pharmacists' Federation = Federazione Ordini Farmacisti Italiani)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Pharmacies must have: 1. An area for private consultation with patients 2. Internet connection at the place of the consultation Pharmacists must: 1. Be qualified and registered with the Italian Pharmacy Board practicing in Italy 2. Have at least 1 year of experience in providing advice to patients 3. Already provide one or more services such as blood pressure monitoring, smoking cessation, cholesterol monitoring, signposting and food intolerance testing to demonstrate advanced consultation skills and experience 4. Be able to attend training sessions Patient selection will take place over the same defined period for all 360 pharmacists: before baseline. Patients will be identified by pharmacists from their medication history, from their prescriptions, or by referral from general practitioners, according to inclusion and exclusion criteria: 1. Age at least 18 years old 2. Diagnosed with asthma, for at least 6 months before enrolment to the study 3. Have at least one prescription for asthma medication with the Anatomical, Therapeutic Chemical Classification R03: drugs for obstructive airways disease
Exclusion criteria
Exclusion criteria: Pharmacies do not have: 1. Internet access 2. Consultation room Pharmacists: 1. Involved in any other clinical pharmacy research project Patients: 1. Have terminal illness (an advanced stage of a disease with an unfavourable prognosis and no known cure) as identified by the pharmacists through the prescription coding 2. Are currently enrolled in another clinical trial 3. Do not self-administer their inhaler 4. Do not have the ability to communicate well in Italian (both verbally and in writing)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of asthma, assessed with the Asthma Control Test score | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Number of active ingredients used by patients, as reported by patients 2. Number of pharmaceutical care issues identified during provision of the I-MUR service 3. Patients’ adherence to asthma medication during and after the I-MUR service provision, measured with questions embedded in the I-MUR instrument 4. Overall health-care costs, estimated on the basis of the severity of asthma, before, during and after provision of the I-MUR service | — |
Countries
Italy
Outcome results
None listed